Mexicor solution 50mg/ml ampoules 5ml 20pcs

Composition

Active ingredient: ethylmethylhydroxypyridine succinate 50 mgm Auxiliary substances: succinic acid; disodium edetate;water for injection

Pharmacological action

An antioxidant preparation.

Mexicor reduces the manifestations of oxidative stress by inhibiting free radical lipid peroxidation and increasing the activity of the antioxidant system of enzymes. Mexicor improves cellular energy exchange by activating the energy-synthesizing functions of mitochondria, enhancing the compensatory activation of aerobic glycolysis, and reducing the degree of inhibition of oxidative processes in the Krebs cycle.

The energy-synthesizing effect of the drug is associated with an increase in the delivery and consumption of succinate by cells, the realization of the phenomenon of rapid succinic acid oxidation by succinate dehydrogenase, and activation of the mitochondrial respiratory chain.

When the Mexicor preparation is dissociated in a cell into succinate and a 3-hydroxypyridine derivative (base), the base exhibits a powerful antioxidant effect that stabilizes cell membranes and restores the functional activity of cells. Reduces the viscosity of the cell membrane, increases its fluidity, and has a modulating effect on membrane-bound enzymes (calcium-independent phosphodiesterase, adenylate cyclase, and acetylcholinesterase), ion channels, and receptor complexes, which helps preserve the structural and functional integrity of biomembranes, improves neurotransmitter transport, and synaptic transmission.

The drug improves brain metabolism and blood supply to the brain, improves microcirculation and rheological properties of blood, reduces platelet aggregation.

Improves the functional state of the ischemic myocardium, contractile function of the heart, and also reduces the manifestations of systolic and diastolic dysfunction of the left ventricle.

In conditions of coronary insufficiency, it increases the collateral blood supply to the ischemic myocardium and activates energy-synthesizing processes in the ischemic zone, which helps preserve the integrity of cardiomyocytes and maintain their functional activity. It effectively restores myocardial contractility in patients with reversible cardiac dysfunction, which is a significant reserve for increasing the contractility of the heart in patients with coronary artery disease complicated by heart failure.

In patients with stable angina pectoris, it increases exercise tolerance and antianginal activity of nitrates, improves the rheological properties of blood. The addition of Mexicor to standard CHD therapy improves the clinical condition of patients, increasing exercise tolerance and improving the quality of life.

Mexicor stabilizes the membrane structures of the vascular wall, inhibits platelet aggregation, normalizes microcirculation disorders in the early stages of atherogenesis, has a hypolipidemic effect, reduces the content of total cholesterol and LDL.

Mexicor has a neuroprotective effect on the functional activity and metabolism of the ischemic brain, increases the stability of blood circulation in the brain under hypoperfusion conditions, and prevents a decrease in blood flow to the brain in the reperfusion period after ischemia.

The drug helps to adapt to the damaging effects of ischemia by inhibiting the depletion of carbohydrate reserves, blocking the post-ischemic decline in the utilization of glucose and oxygen by the brain, and preventing the progressive accumulation of lactate. At the same time, the indicators of autoregulatory reactions of cerebral vessels improve.

Mexicor has nootropic properties, prevents and reduces learning and memory disorders that occur in acute and chronic vascular diseases of the brain, with mild and moderate cognitive disorders of various origins, has an antioxidant effect, increases concentration and performance.

The inclusion of Mexicor in the complex therapy of patients with acute cerebrovascular accident reduces the severity of clinical manifestations of stroke and improves the course of the rehabilitation period.

Mexicor has a selective anxiolytic effect, which is not accompanied by sedation and muscle relaxation, eliminates anxiety, fear, tension, anxiety, increases adaptation and emotional status.

Pharmacokinetics

Suction

After oral use, the Active ingredient of Mexicor is rapidly and completely absorbed from the gastrointestinal tract. The time to reach Cmax in blood plasma is 0.46-0.50 hours.

Distribution

It is rapidly distributed in organs and tissues. The average time of drug distribution in the body is 4.9-5.2 hours.

Metabolism

It is metabolized in the liver by glucuronidation. 5 metabolites were identified: 3-oxypyridine phosphate-is formed in the liver and breaks down into phosphoric acid and 3-oxypyridine with the participation of alkaline phosphatase; the 2nd metabolite is pharmacologically active, is formed in large quantities and is detected in the urine 1-2 days after taking the drug; the 3rd-is excreted in large quantities by the kidneys; the 4th and 5th – glucuronconjugates.

Removing

T1/2 – 4.7-5.0 On average,0.3% of the unchanged drug and 50% of the administered dose are excreted in the urine in 12 hours in the form of glucuronoconjugate. The most intensively Active ingredient and its glucuronoconjugates are eliminated in the first 4 hours after taking the drug.

Renal excretion rates of the unchanged drug and its metabolites are highly variable individually.

Indications

• as part of the complex therapy of acute myocardial infarction (from the first day);
• as part of the complex therapy of ischemic stroke;
• dyscirculatory encephalopathy (including atherosclerotic genesis);
• mild and moderate cognitive disorders of various origins.

Contraindications

• acute liver function disorders;
• acute renal function disorders;
• children and adolescents under 18 years of age (efficacy and safety have not been established);
• pregnancy;
• lactation (breastfeeding);
• hypersensitivity to the components of the drug.

Side effects

With intravenous use, especially jet, it is possible:

From the digestive system:  dryness and metallic taste in the mouth.

Respiratory system disorders:  sore throat, chest discomfort and lack of air.

Other services:  feeling of” spreading ” warmth throughout the body.

As a rule, these phenomena are caused by a high rate of drug use and are transient in nature.

Against the background of prolonged use of the drug, the following side effects may occur: :

From the digestive system:  nausea, flatulence.

From the central nervous system:  sleep disorders (drowsiness or difficulty falling asleep).

Interaction

Mexicor® potentiates the effect of nitrates.

How to take, course of use and dosage

In the treatment of acute myocardial infarction Mexicor® is administered intravenously or intramuscularly for 14 days against the background of traditional therapy, including nitrates, beta-blockers, ACE inhibitors, thrombolytics, anticoagulants and antiplatelet agents, as well as symptomatic agents as indicated.

In the first 5 days, to achieve maximum effect, the drug should be administered intravenously, and in the next 9 days, the drug can be administered intravenously.

Intravenous use of the drug is carried out by drip infusion, slowly (to avoid side effects), in saline or 5% dextrose (glucose) solution in a volume of 100-150 ml for 30-90 minutes. If necessary, a slow jet injection of the drug lasting at least 5 minutes is possible.

use of the drug (IV or iv) is carried out 3 times / day, every 8 hours. The daily therapeutic dose is 6-9 mg/kg of body weight, a single dose is 2-3 mg/kg of body weight. The maximum daily dose should not exceed 800 mg, a single dose-250 mg.

In acute disorders of cerebral circulation (ischemic stroke) Mexicor® is used as part of complex therapy for the first 2-4 days in / in drops of 200-300 mg 2-3 times a day, then in / m 100 mg 3 times a day. The duration of treatment is 10-14 days. In the future, the drug is prescribed orally in the form of capsules of 100 mg 2 times/day for 14 days and 100 mg 3 times/day for the next 7 days. The frequency and duration of repeated courses of therapy is determined by the doctor.

With dyscirculatory encephalopathy in the decompensation phase Mexicor® should be administered intravenously in a jet or drip at a dose of 100 mg 2-3 times a day for 14 days. Then the drug is administered intravenously at 100 mg / day for the next 2 weeks. In the future, the drug is prescribed in the form of capsules of 100 mg 2-4 times a day, the frequency and duration of therapy courses is determined by the doctor.

For the course prevention of dyscirculatory encephalopathy Mexicor® is administered intravenously at a dose of 100 mg 2 times / day for 10-14 days.

For the treatment of mild to moderate cognitive disorders Mexicor® is administered intravenously at a dose of 100-300 mg / day for 14 days. If necessary, in the future, the drug is used in capsule form of 100 mg 2-4 times / day (on the recommendation of a doctor) without limiting the duration of treatment.

Overdose

Symptoms:  sleep disorders (insomnia), in some cases drowsiness; with intravenous use, in rare cases, a slight and short-term (up to 1.5-2 hours) increase in blood pressure.

Treatment:  the development of overdose symptoms, as a rule, does not require the use of cupping agents, these symptoms of sleep disorders disappear independently within a day.In particularly severe cases, it is recommended to use one of the sleeping pills and anxiolytics for oral use (nitrazepam 10 mg, oxazepam 10 mg or diazepam 5 mg). With an excessive increase in blood pressure, antihypertensive agents are used.

Special instructions

In acute myocardial infarction, acute (ischemic stroke) and chronic (dyscirculatory encephalopathy) disorders of the cerebral circulation after the completion of parenteral use of the drug, to maintain the achieved therapeutic effect, it is recommended to continue using the drug Mexicor® in the dosage form of capsules (100 mg 3 times / day). The duration of therapy is determined by the doctor.

Storage conditions

In a dark place, at a temperature not exceeding 25 °C. Keep out of reach of children.

Shelf life

3 years

Active ingredient

Ethylmethylhydroxypyridine Succinate

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection and infusion

Purpose

For adults as directed by your doctor

Indications

Myocardial infarction, Consequences of stroke, Atherosclerosis, Concussion and other traumatic brain injuries, Vegetative-vascular disorders, Cerebral circulation disorders